NJAAIS 2018 Annual Teaching Day

September 28, 2018

This meeting focuses on concerns and educational needs of allergists and immunologists.  Topics include: food allergy, atopic dermatitis and immunotherapy. Both national and regional thought leaders will provide an outstanding educational opportunity to all attendees.
 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and New Jersey Allergy, Asthma & Immunology Society (NJAAIS) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Funding

This activity is not supported by educational grants.

Target Audience

Practicing allergists and allied healthcare providers in the field of allergy and immunology.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe the role of the allergist in diagnosing common, non-allergic skin conditions
  • Describe the role of the allergist in diagnosing and treating allergic skin conditions
  • Discuss the Practice Parameter summary statements for hymenoptera hypersensitivity.
  • Identify patients who are appropriate to screen and treat for venom hypersensitivity
  • Learn the currently accepted clinical presentation of mast cell activation syndrome and other systemic mast cell diseases, and be able to apply gained knowledge to order new diagnostic tests and treat the mast cell patient
  • Identify cutaneous manifestations of the primary immunodeficiency patient
  • Describe the role of the allergist in the diagnosis and treatment of eosinophilic esophagitis
  • Describe recent trials and updates in food allergy
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

Mirna Chehade, MD, MPH (Speaker)

Consultant:  Shire, Allakos

Contracted Research: Nutricia, Regeneron

Mariana Castells, MD (Speaker)

Consultant: Sanofi, Lytix Biopharma, Bentham Science

Independent contractor: Genentech

Advisory Board: Merck

David Golden, MD (Speaker)

Speaker: Genetech, Stallergenes/Greer

Independent contractor: Genetech, Stallergenes/Greer

Author: UpToDate

Edwin Kim, MD (Speaker)

Consultant: DBV Technologies, Aimmune therapeutics

Advisory Board: DBV Technologies

The following have nothing to disclose:

Jacqueline Ross, MD (Program Director)
Satya Narisety, MD (President)

James Treat, MD (Speaker)

Markus Boos, MD, PhD (Speaker)

Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
Course opens: 
09/28/2018
Course expires: 
09/28/2020
Event starts: 
09/28/2018 - 7:30am
Event ends: 
09/28/2018 - 4:30pm
Cost:
$0.00
Rating: 
0

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and New Jersey Allergy, Asthma & Immunology Society (NJAAIS) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Funding

This activity is not supported by educational grants.

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance

Accreditation Period

Course opens: 
09/28/2018
Course expires: 
09/28/2020

Price

Cost:
$0.00
Please login or create an account to take this course.